Abion Inc. is a South Korean clinical-stage biopharmaceutical company committed to the discovery and development of innovative medicines targeting intractable diseases, with a primary focus on oncology and rare conditions. Leveraging advanced drug development platforms and a dedicated research team, Abion strives to translate scientific breakthroughs into effective therapies that address significant unmet medical needs globally. The company's pipeline includes promising candidates like ABN401, a c-MET inhibitor.
Serves as the central hub for all corporate functions, including research and development of novel therapeutics, clinical trial management, strategic planning, and administrative operations.
Strategically situated within the Songdo Bio-Valley, a leading South Korean biotechnology cluster, offering access to state-of-the-art research infrastructure, a skilled talent pool, and a collaborative R&D ecosystem.
Characterized by a strong emphasis on scientific innovation, rigorous research methodologies, and collaboration. The culture likely fosters intellectual curiosity and a patient-centric approach to drug development, typical of clinical-stage biopharmaceutical firms.
Its location in Songdo Bio-Valley is critical for Abion's mission, enabling synergies with other biotech entities, academic institutions, and access to specialized facilities essential for advancing its drug pipeline.
While headquartered in South Korea, Abion Inc. maintains a global outlook, particularly in its clinical development programs which often involve international sites, including the United States for key trials like ABN401. The company actively seeks to bring its innovative therapies for cancer and rare diseases to patients worldwide by engaging with global regulatory bodies and pursuing international research collaborations and potential commercialization partnerships.
C-702, Songdo Bio-Valley, 15 Songdomirae-ro
Incheon
Yeonsu-gu
Republic of Korea
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Abion' leadership includes:
Abion has been backed by several prominent investors over the years, including:
No major executive hires or exits at Abion Inc. have been widely reported in readily available English-language public sources over the last 12 months, suggesting leadership stability. Key executive information is typically disclosed via Korean financial regulatory filings (DART).
Discover the tools Abion uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Abion Inc. likely utilizes a standardized email format for its employees, common in professional Korean companies. While the exact predominant pattern is not publicly confirmed, typical structures often involve combinations of the employee's Romanized name and the company domain, abionbio.com.
[firstinitial][lastname]@abionbio.com
Format
dshin@abionbio.com (example for Dongho Shin)
Example
65%
Success rate
KED Global / The Bell • January 24, 2024
Abion Inc. has successfully completed patient enrollment for the U.S. Phase 2 clinical trial of ABN401, its lead c-MET inhibitor candidate. This milestone paves the way for accelerating its entry into the global market for treating cancers driven by MET alterations....more
The Korea Herald • January 10, 2024
Abion Inc. announced promising results from its phase 2 clinical trial of ABN401, a c-MET targeted therapy, demonstrating a complete remission in a patient with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. The data highlights ABN401's potential as an effective treatment....more
Korea Biomedical Review • November 2, 2023
Abion's ABN401, a treatment for non-small cell lung cancer (NSCLC), has received orphan drug designation (ODD) from the Ministry of Food and Drug Safety (MFDS) in Korea. This designation is for drugs treating rare diseases and offers benefits like expedited review....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Abion, are just a search away.